Biotech Values

[ghmm]

Thanks genisi. I figured Ventavis users would switch in droves but not so quickly. I think the patents on Ventavis expire soon and wouldn't be surprised if Actelion stops promoting it completely. To me the bigger question was would sub-q and IV users try to switch perhaps adding an Oral. My guess is it is in the 20% range but that is a guess and I would think the high dose users would be less likely to switch (which wouldn't hurt revenues) especially since there isn't much data on higher dosing of the inhaled formulation.

FYI Dr. Rothblatt probably refers she then he buts its complicated so I generally try to just go by Dr. Rothblatt